Thermo Fisher Scientific VEGF Monoclonal Antibody (OTI2B9), TrueMAB

Applications

• Western Blot (WB): Tested dilution 1:500

Product Specifications

Product Specific Information

For reconstitution, add 100 µL of distilled water to obtain a final antibody concentration of approximately 1 mg/mL.
For conjugation experiments, perform an additional desalting step (recommended: Zeba Spin Desalting Columns, 7K MWCO, 0.5 mL, Product #89882).

Target Information

VEGF (vascular endothelial growth factor) is a 45 kDa homodimeric, disulfide-linked glycoprotein involved in angiogenesis, promoting tumor progression and metastasis. It affects vascular endothelium by enhancing endothelial cell viability, mitogenesis, chemotaxis, and vascular permeability.
The VEGF family includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, and PIGF. VEGF and its receptor system are key regulators of angiogenic signaling. Tumor growth often depends on angiogenesis, with VEGF identified as the most potent angiogenic cytokine in this process.
Five isoforms of VEGF are produced by alternative splicing from a single gene. These isoforms bind to tyrosine kinase receptors FLT-1 (VEGFR-1) and FLK-1/KDR (VEGFR-2), primarily expressed on endothelial cells. VEGF and its receptors are essential for embryonic vasculature development.
An alternatively spliced form of FLT1 produces a soluble protein (sFLT1) that binds VEGF with high affinity, inhibiting angiogenesis. Elevated VEGF levels are associated with POEMS syndrome (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy, Skin changes), also known as Crow-Fukase syndrome.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.